Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Induction of tissue factor expression by anti-β2-glycoprotein I is mediated by tumor necrosis factor α.

Hollerbach A, Müller-Calleja N, Canisius A, Orning C, Lackner KJ.

J Thromb Thrombolysis. 2019 Oct 15. doi: 10.1007/s11239-019-01970-2. [Epub ahead of print]

PMID:
31612355
2.

Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis.

Müller-Calleja N, Hollerbach A, Ritter S, Pedrosa DG, Strand D, Graf C, Reinhardt C, Strand S, Poncelet P, Griffin JH, Lackner KJ, Ruf W.

Blood. 2019 Oct 3;134(14):1119-1131. doi: 10.1182/blood.2019001530. Epub 2019 Aug 21.

PMID:
31434703
3.

Platelet Activation by Antiphospholipid Antibodies Depends on Epitope Specificity and is Prevented by mTOR Inhibitors.

Hollerbach A, Müller-Calleja N, Ritter S, Häuser F, Canisius A, Orning C, Jurk K, Lackner KJ.

Thromb Haemost. 2019 Jul;119(7):1147-1153. doi: 10.1055/s-0039-1685453. Epub 2019 Apr 24.

PMID:
31018220
4.

Cofactor-Independent Antiphospholipid Antibodies: Implications for Pathogenesis, Diagnosis, and Treatment of Antiphospholipid Syndrome.

Lackner KJ, Müller-Calleja N.

Hamostaseologie. 2019 Jun;39(2):188-194. doi: 10.1055/s-0038-1675355. Epub 2018 Nov 12.

PMID:
30419590
5.

Pathogenesis of antiphospholipid syndrome: recent insights and emerging concepts.

Lackner KJ, Müller-Calleja N.

Expert Rev Clin Immunol. 2019 Feb;15(2):199-209. doi: 10.1080/1744666X.2019.1546578. Epub 2018 Dec 6.

PMID:
30412684
6.

Laboratory criteria for antiphospholipid syndrome: comment.

Lackner KJ, Müller-Calleja N.

J Thromb Haemost. 2018 Oct;16(10):2115-2116. doi: 10.1111/jth.14237. Epub 2018 Aug 16. No abstract available.

PMID:
30007114
7.

Response to: 'Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus' by Wang et al.

Müller-Calleja N, Lackner KJ.

Ann Rheum Dis. 2019 Aug;78(8):e81. doi: 10.1136/annrheumdis-2018-213853. Epub 2018 Jun 26. No abstract available.

PMID:
29945922
8.

Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies.

Müller-Calleja N, Ritter S, Hollerbach A, Falter T, Lackner KJ, Ruf W.

Blood Adv. 2018 May 8;2(9):979-986. doi: 10.1182/bloodadvances.2018017095.

9.

Antiphospholipid antibody-induced cellular responses depend on epitope specificity : implications for treatment of antiphospholipid syndrome.

Müller-Calleja N, Hollerbach A, Häuser F, Canisius A, Orning C, Lackner KJ.

J Thromb Haemost. 2017 Dec;15(12):2367-2376. doi: 10.1111/jth.13865. Epub 2017 Nov 1.

PMID:
29024318
10.

Endosomal Redox Signaling in the Antiphospholipid Syndrome.

Lackner KJ, Manukyan D, Müller-Calleja N.

Curr Rheumatol Rep. 2017 Apr;19(4):20. doi: 10.1007/s11926-017-0647-7. Review.

PMID:
28361335
11.

Mechanisms of Cellular Activation in the Antiphospholipid Syndrome.

Müller-Calleja N, Lackner KJ.

Semin Thromb Hemost. 2018 Jul;44(5):483-492. doi: 10.1055/s-0036-1597290. Epub 2017 Feb 6. Review.

PMID:
28166601
12.

Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase.

Müller-Calleja N, Manukyan D, Canisius A, Strand D, Lackner KJ.

Ann Rheum Dis. 2017 May;76(5):891-897. doi: 10.1136/annrheumdis-2016-210012. Epub 2016 Nov 30.

PMID:
27903507
13.

Pathophysiological insights into the antiphospholipid syndrome.

Lackner KJ, Manukyan D, Müller-Calleja N.

Hamostaseologie. 2017 Aug 8;37(3):202-207. doi: 10.5482/HAMO-16-07-0020. Epub 2016 Oct 27. Review.

PMID:
27786332
14.

Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma: reply.

Lackner KJ, Müller-Calleja N.

J Thromb Haemost. 2016 Dec;14(12):2563-2564. doi: 10.1111/jth.13523. Epub 2016 Oct 20. No abstract available.

15.

Antiphospholipid Antibodies: Their Origin and Development.

Lackner KJ, Müller-Calleja N.

Antibodies (Basel). 2016 Jun 2;5(2). pii: E15. doi: 10.3390/antib5020015. Review.

16.

Antiphospholipid antibodies in a large population-based cohort: genome-wide associations and effects on monocyte gene expression.

Müller-Calleja N, Rossmann H, Müller C, Wild P, Blankenberg S, Pfeiffer N, Binder H, Beutel ME, Manukyan D, Zeller T, Lackner KJ.

Thromb Haemost. 2016 Jul 4;116(1):115-23. doi: 10.1160/TH15-12-0947. Epub 2016 Apr 21.

PMID:
27098658
17.

Distribution of antiphospholipid antibodies in a large population-based German cohort.

Manukyan D, Rossmann H, Schulz A, Zeller T, Pfeiffer N, Binder H, Münzel T, Beutel ME, Müller-Calleja N, Wild PS, Lackner KJ.

Clin Chem Lab Med. 2016 Oct 1;54(10):1663-70. doi: 10.1515/cclm-2016-0014.

PMID:
27028736
18.

Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma.

Lackner KJ, Müller-Calleja N.

J Thromb Haemost. 2016 Jun;14(6):1117-20. doi: 10.1111/jth.13320. Epub 2016 Apr 26.

19.

Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice.

Manukyan D, Müller-Calleja N, Jäckel S, Luchmann K, Mönnikes R, Kiouptsi K, Reinhardt C, Jurk K, Walter U, Lackner KJ.

J Thromb Haemost. 2016 May;14(5):1011-20. doi: 10.1111/jth.13263. Epub 2016 Mar 16.

20.

Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome.

Müller-Calleja N, Köhler A, Siebald B, Canisius A, Orning C, Radsak M, Stein P, Mönnikes R, Lackner KJ.

Thromb Haemost. 2015 May;113(5):1071-83. doi: 10.1160/TH14-07-0628. Epub 2015 Jan 15.

PMID:
25589411

Supplemental Content

Loading ...
Support Center